Potent HIV Protease Inhibitor Against HIV/AIDS

Back to all technologies
Download as PDF
2017-GHOS-67663
HIV-1 protease inhibitors are the key component of current antiretroviral treatment (ART) of HIV infection and AIDS. The majority of today's FDA approved protease inhibitors do not show efficacy because of the emergence of drug resistance. Darunavir, a leading protease inhibitor drug, is widely used for the treatment of patients harboring drug-resistant HIV variants. However, after long-term use, darunavir-resistant HIV-1 variants are emerging and there are very limited options to treat these patients.

Researchers at Purdue University have developed a new class of inhibitors that have shown exceptional potency against multidrug resistant (MDR) HIV-1 variants. The developed compounds are novel and show better drug-resistant properties.

Advantages:
-Fight drug-resistant HIV-1 variants
-New compounds show better drug-resistant properties

Potential Applications:
-Pharmaceutical industry
-HIV/AIDS treatment
Nov 9, 2017
PCT-Patent
WO
(None)
(None)

Nov 9, 2016
Provisional-Patent
United States
(None)
(None)
Purdue Office of Technology Commercialization
1801 Newman Road
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486
Email: otcip@prf.org